Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
Cesar Giancarlo Gentille SanchezHumaira SarfrazJitesh JoshiJasleen RandhawaShilpan ShahSai Ravi PingaliPublished in: Cancer reports (Hoboken, N.J.) (2022)
In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.
Keyphrases